Ex Vivo Anti-sEng Immunoadsorption for Pre-Eclampsia Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for pregnancy-related hypertensive disorders such as pre-eclampsia and eclampsia are limited in effectiveness, failing to target the underlying causes and posing risks to both mother and fetus, with existing medications like magnesium sulfate and antihypertensives causing side effects and premature delivery being the primary interventions.

Innovation Solution

The use of anti-sEng antibodies or sEng-binding fragments to decrease soluble Endoglin (sEng) levels in a subject's blood by binding and removing it ex vivo, thereby targeting the underlying cause of these disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current standard treatments (magnesium sulfate, antihypertensives) are used to manage maternal symptoms, then maternal symptoms are temporarily relieved, but the underlying cause of pre-eclampsia is not targeted and side effects occur

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidside effects of medications

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The invention extracts and removes the harmful substance sEng from the patient's blood through immunoadsorption columns containing anti-sEng antibodies. This directly eliminates the underlying pathological factor causing pre-eclampsia symptoms, rather than merely suppressing symptoms with medications that have side effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention introduces anti-sEng antibodies as an intermediary substance that specifically binds to and neutralizes sEng. These antibodies act as mediators between the harmful sEng and the therapeutic goal, providing targeted treatment without the non-specific side effects of traditional antihypertensive medications.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If premature delivery is performed to save the mother's life in severe cases, then maternal mortality is reduced, but significant risks are posed to newborns

Engineering Contradiction:

Improvematernal survivalVSAvoidrisks to newborns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention performs preliminary treatment by removing sEng from the maternal circulation before delivery becomes necessary. This early intervention stabilizes the maternal condition and may allow for delayed delivery, thereby reducing newborn risks while still protecting maternal health.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention converts the harmful effect of sEng accumulation into a therapeutic opportunity by using immunoadsorption to specifically remove it. This transforms a life-threatening condition into a treatable state, potentially avoiding premature delivery and its associated risks to newborns.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Stress or pressure

If blood pressure medications are used to control hypertension in pre-eclampsia, then blood pressure is reduced, but the medications cross the placental barrier and pose direct risks to the fetus

Engineering Contradiction:

Improveblood pressure controlVSAvoidfetal exposure to medications

Core Design Contradiction:

Stress or pressureVSObject-affected harmful factors

Solution Approach 1:

The invention extracts and removes the underlying cause of hypertension (sEng) from the maternal bloodstream through immunoadsorption. This eliminates the need for blood pressure medications that would otherwise cross the placental barrier and expose the fetus to harmful effects.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention uses anti-sEng antibodies as intermediaries that bind to and neutralize sEng in the maternal circulation. This provides a targeted therapeutic mechanism that does not require systemic blood pressure medications, thereby protecting the fetus from medication exposure while still controlling hypertension.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively reduces sEng levels, potentially prolonging pregnancy safely and reducing maternal symptoms without the side effects associated with current treatments, while minimizing risks to the fetus.

Implementation Method 1

bringing the blood or a component thereof (e.g., plasma) into contact with the anti-sEng antibodies or sEng-binding fragments thereof, where the anti-sEng antibodies or sEng-binding fragments thereof are bound to a solid support, to bind sEng in the subject's blood or component thereof to the anti-sEng antibodies or sEng-binding fragments thereof

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS12522665B2Methods and systems for treating or preventing pregnancy-related hypertensive disorders

Publication Date: 2026.01.13 AGGAMIN LLC

AI summary

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sEng antibody bound to a solid support in order to reduce blood levels of sEng. The present invention provides a method of treating or preventing a disorder associated with soluble Endoglin (sEng), such as a pregnancy-related hypertensive disorder, in a subject in need thereof comprising providing ex vivo to the subject anti-sEng antibodies or sEng-binding fragments thereof in an amount sufficient and for a time sufficient to decrease the subject's blood levels of sEng to treat or prevent the disorder associated with sEng in the subject.